TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

Presenter: yoichiro sugizaki

REGISTER for free or LOG IN to view this content

TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

We Recommend